Could glycated hemoglobin be used as a diagnostic tool in diabetes mellitus?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 120, Issue 3, 2010, Pages 109-114

  Drzewoski, Józef ^a   Drozdowska, Agata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Diabetes mellitus; Diagnostic tests; Glycated hemoglobin

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

CARBOHYDRATE METABOLISM; DIABETES MELLITUS; DIAGNOSTIC TEST; EARLY DIAGNOSIS; HUMAN; HYPERGLYCEMIA; RELIABILITY; REVIEW;

EID: 77951014744     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.901     Document Type: Review

References (51)

1. King H, Alberti KG, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care. 1998; 21: 1414-1431.
2. Mooy JM, Grootenhuis PA, de Vries H, et al. Prevalence and determinants of glucose intolerance in a Dutch Caucasian population: the Hoom Study (Short Report). Diabetes Care. 1995; 18: 1270-1273.
3. Harris ML. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care. 1993; 16: 642-652.
4. Sato KK, Hayashi T, Harita N, et al. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes. The Kansai Healthcare Study. Diabetes Care. 2009; 32: 644-646.
5. Saudek CD, Herman WH, Sacks DB, et at. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab. 2008; 93: 2447-2453. (Pubitemid 352008502)
6. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care. 2009; 32: 1327-1334.
7. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; 26 (Suppl 1): S5-S20.
8. Gabir MM, Hanson RL, Dabelea D, et al. Plasma glucose and prediction of microvascular disease and mortality. Diabetes Care. 2000; 23: 1113-1118.
9. Ollerton RL, Playle R, Ahmed K, et al. Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care. 1999; 22: 394-398. (Pubitemid 29106892)
10. Sacks DB, Bruns DE, Goldstein DE, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2002; 48: 436-472. (Pubitemid 34174577)
11. Ko GTC, Chan JCN, Tsang LWW, et al. Combined use of fasting plasma glucose and HbA1c predicts the progression to diabetes in Chinese subjects. Diabetes Care. 2000; 23: 1770-1773.
12. Geberhiwot T, Haddon A, Labib M. HbA1c predicts the likelihood of having impaired glucose tolerance in high-risk patients with normal fasting plasma glucose. Ann Clin Biochem. 2005; 42: 193-195. (Pubitemid 40694958)
13. Abdul-Ghani MA, Williams K, Defronzo RA, et al. What is the best predictor of future type 2 diabetes? Diabetes Care. 2007; 30: 1544-1548.
14. Gomez-Perez FJ, Aguilar-Salinas CA, Lopez-Alvarenga JC, et al. Lack of agreement between the World Health Organization category of impaired glucose tolerance and the American Diabetes Association category of impaired fasting glucose. Diabetes Care. 1998; 21: 1886-1888. (Pubitemid 28478287)
15. Jesudason DR, Dunstan K, Leong D, et al. Macrovascular risk and diagnostic criteria for type 2 diabetes. Diabetes Care. 2003; 26: 485-490.
16. Drzewoski J, Czupryniak L. Concordance between fasting and 2-h post-glucose challenge criteria for the diagnosis of diabetes mellitus and glucose intolerance in high risk individuals. Diab Med. 2001; 18: 29-31. (Pubitemid 32158105)
17. Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of type 2 diabetes: a systemic review. Diabet Med. 2007; 24: 333-343. (Pubitemid 46452406)
18. Sabanayagam C, Liew G, Tai ES, et al. Relationship between glycated hemoglobin and microvascular complications: is there a natural cut-off point for the diagnosis of diabetes. Diabetologia. 2009; 52: 1279-1289.
19. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA. 2006; 295: 1688-1697.
20. Koenig RJ, Peterson CM, Jones RL, et al. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med. 1976; 295: 417-420.
21. Herman WH, Ma Y, Uwaifo G, et al. The Diabetes Prevention Program Research Group. Differences in A1c by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007; 30: 2756-2758.
22. Tarim O, Kucukerdogan A, Gunay U, et al. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. Pediatr Int. 1999; 41: 357-362.
23. Roberts WL, Safar-Pour S, De BK, et al. Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods. Clin Chem. 2005; 51: 776-778.
24. Chachou A, Randoux C, Millart H, et al. Influence of in vivo hemoglobin carbamylation on HbA1c measurements by various methods. Clin Chem Lab Med. 2000; 38: 321-326. (Pubitemid 30444959)
25. Nathan DM, Francis TB, Palmer JL. Effect of aspirin on determination of glycosylated hemoglobin. Clin Chem. 1983; 29: 466-469.
26. Davie SJ, Gould BJ, Yudkin JS. Effect of vitamin C on glycosylation of proteins. Diabetes Care. 1992; 41: 167-173.
27. Ceriello A, Giugliano D, Quatraro A, et al. Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications? Diabetes Care. 1991; 14: 68-72.
28. Selvin E, Crainiceanu CM, Brancati FL, et al. Short-term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med. 2007; 167: 1545-1551. (Pubitemid 47124186)
29. Waden J, Forsblom C, Thom LM, et al. A1c variability predicts incident cardiovascular events, microalbuminuna, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes. 2009; 58: 2649-2655.
30. Roubicek M, Vines G, Gonzalez Sanguineti A. Use of HbA1c in screening for diabetes. Diabetes Care. 1998; 21: 1577-1578.
31. Goldstein DE. Isn't it time to retire the oral glucose tolerance test for diabetes screening and diagnosis? Diabetes Care. 1998; 21: 1215-1216.
32. Rohlfing CL, Wiedmeyer HM, Little RR, et al. Defining the relationship between plasma glucose and HbA(1c): Analysis of glucose profiles and HbA(1c) in the diabetes control and complications trial. Diabetes Care. 2002; 25: 275-278.
33. Wiener K, Roberts NB. The relative ments of haemoglobin A1c and fasting plasma glucose as first-line diagnostic test for diabetes mellitus in non-pregnant subjects. Diabet Med. 1998; 15: 558-563. (Pubitemid 28319937)
34. Buell C, Kermah D, Davidson MB. Utility of A1C for diabetes screening in the 1999-2004 NHANES population. Diabetes Care. 2007; 30: 2233-2235.
35. Davidson MB, Schriger DL, Peters AL, et al. Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. JAMA. 1999; 281: 1203-1210.
36. Perry RC, Shankar RR, Fineberg N, et al. HbA1c Measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose. The Early Diabetes Intervention Program (EDIP). Diabetes Care. 2001; 24: 465-471.
37. U.K. Prospective Diabetes Study Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-852.
38. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications of insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986.
39. Jimeno-Mollet J, Molist-Brunet N, Franch-Nadal J, et al. Diagnosing type 2 diabetes mellitus: in primary care, fasting plasma glucose and glycosylated haemoglobin do the job. Aten Primaria. 2004; 34: 222-228.
40. Little RR, England D, Wiedmeyer HM, et al. Glycated haemoglobin predicts progression to diabetes mellitus in Pima Indians with impaired glucose tolerance. Diabetologia. 1994; 37: 252-256.
41. Likhan T, Aulakh TS, Singh BM, et al. Does HbA1C predict isolated impaired fasting glycaemia in the oral glucose tolerance test in subjects with impaired fasting glycaemia? Ann Clin Biochem. 2008; 45: 418-420.
42. Selvin E, Zhu H, Brancati FL. Elevated A1C in Adults Without a History of Diabetes in the U.S. Diabetes Care. 2009; 32: 828-833.
43. Greci LS, Kailasam M, Malkani S, et al. Utility of HbA1c levels for diabetes case finding in hospitalized patients with hyperglycemia. Diabetes Care. 2003; 26(4): 1064-1068. (Pubitemid 36929249)
44. Costa A, Conget I, Treserras R, et al. The usefulness of basal blood glucose and glycosylated hemoglobin for the detection of abnormal glucose tolerance in the relatives of patients with type-2 diabetes mellitus. Med Clin Barc. 1999; 112: 241-244.
45. Zhang XM, Ding YL. [Glycosylated hemoglobin test in gestational abnormal glucose metabolism). Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2008; 33: 85-88. Chinese.
46. Shah S, Kublaoui BM, Oden JD, et al. Screening for type 2 diabetes in obese youth. Pediatrics. 2009; 124: 573-579.
47. Icks A, Haastert B, Gandjour A, et al.; the KORA Study Group. Cost-effectiveness analysis of different screening procedures for type 2 diabetes. Diabetes Care. 2004; 27: 2120-2128.
48. Mitka M. Hemoglobin A1c poised to become preferred test for diagnosing diabetes. JAMA. 2009; 301: 1528.
49. Rollins G. A new role for hemoglobin A1c. Should it be used to screen for diabetes? Clin Lab News. 2008; 34: 1-4.
50. Bloomgarden Z. A1c: recommendations, debates, and questions. Diabetes Care. 2009; 32: e141-e147.
51. Clinical Practice Recommendations. Diabetes Care. 2010; 33 (Suppl 1): 62-69.